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Optineurin is a gene associated with normal tension glaucoma (NTG) and amyotrophic lateral sclerosis (ALS). Foci
formation and functional consequences including Golgi fragmentation, impairment of vesicle trafficking and
apoptosis were observed previously upon overexpression and/or mutation of optineurin.
In the current study, a total of 15 GFP tagged constructs that included NTG (E50K and 2 bp-AG insertion), ALS (exon
5 deletion, R96L, Q398X, and E478G) and non-disease (L157A and D474N) associated mutants and a series of deletion
fragments were cloned into mammalian expression vectors and transfected into RGC5 and/or Neuro2A cells to
evaluate whether their expression confer the optineurin phenotypes. The cells were monitored for foci formation and
stained by immunofluorescence with anti-GM130 to analyze the Golgi integrity. Transferrin uptake experiments were
performed to evaluate the protein trafficking process and apoptosis was assessed with the active caspase 3/7 detection
kit. We demonstrated that cells expressing E50K and R96L optineurin exhibited all of the optineurin phenotypes. Q398X
mutant did not induce foci formation, but triggered Golgi fragmentation, impairment of transferrin uptake and increase
in apoptosis. The 2 bp-AG insertion mutant had a nuclear localization, compromised the transferrin uptake and strongly
induced apoptosis. The foci formation, which might not predict the rest of the phenotypes, appeared to require both
the leucine zipper and ubiquitin binding domains of the optineurin sequence. Interactions of optineurin with proteins
including Rab8, myosin VI, huntingtin and transferrin receptor might directly determine whether the Golgi and protein
trafficking phenotypes would be manifested. Examination of mutants and deletion fragments located at various sites of
optineurin gene provide clues as to what regions of the gene may play a critical role in the development of pathologic
consequences.
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Optineurin, a 67-kDa protein, has attracted much atten-
tion in the neuroscience fields in recent years. It was
first isolated in 1998 by Li et al. (1998) in yeast 2-hybrid
screen and has been shown subsequently (Schwamborn
et al. 2000) to have a strong homology to NF-κB essen-
tial molecule (NEMO). In 2002 (Rezaie et al. 2002), the
optineurin or “optic neuropathy inducing” gene was
identified to be a candidate gene of primary open-angle
glaucoma (POAG), the most common form of glaucoma,
one of the leading causes of irreversible bilateral blind-
ness worldwide. POAG, characterized by degeneration of
retinal ganglion cells and progressive axonal and visual
field loss, is age-related and frequently associated with* Correspondence: beatyue@uic.edu; hying@uic.edu
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in any medium, provided the original work is pincreased intraocular pressure (Stamer and Acott 2012).
It is genetically heterogeneous, caused by several suscep-
tibility genes (Allingham et al. 2009; Fingert 2011; Wiggs
2012) and also environmental factors (Wiggs 2012).
Optineurin was found to be linked in particular to normal
tension glaucoma (NTG) (Rezaie et al. 2002; Sarfarazi and
Rezaie 2003), a subtype of POAG.
More recently, mutations in optineurin were also re-
ported to be associated with amyotrophic lateral scler-
osis (ALS) (Maruyama et al. 2010; Deng et al. 2011).
Optineurin was noted to be localized in pathological
structures in ALS, neurofibrillary tangles and dystrophic
neuritis in Alzheimer’s disease, as well as Lewy bodies
and Lewy neuritis in Parkinson’s disease (Osawa et al.
2011). In addition, optineurin was identified as one of the
genetic risk factor for Paget’s disease of bone (Albagha
et al. 2010; Chung et al. 2010).an open access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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protein (Li et al. 1998). The protein consists of a NEMO-
like domain, leucine zipper motif, multiple coiled-coil mo-
tifs, an ubiquitin binding domain (UBD), a microtubule
associated protein 1 light chain 3 (LC3)-interacting motif,
and a carboxyl (C)-terminal zinc finger (Figure 1) (Ying
and Yue 2012). Optineurin is a cytosolic protein that is
not secreted (Ying et al. 2010). It is expressed in many
non-ocular tissues such as the brain and the heart as wellFigure 1 Schematic representation of mutants and deletion fragment
(1–577) optineurin protein consists of a leucine zipper (LZ, dark blue) doma
ubiquitin binding domain (UBD, yellow) and a zinc finger (ZnF, purple) mo
R96L and E478G are associated with ALS. L157A and D474N mutations hav
optineurin. The glaucoma-associated 2 bp-AG insertion mutation, ALS-as
of the protein into a 1–148, 1–55 fragment and 1–398 fragment respectivelyas in ocular tissues including the retina and the trabecular
meshwork (Schwamborn et al. 2000; Sarfarazi and Rezaie
2003; Ying and Yue 2012).
Optineurin has been shown to be a negative regulator of
the NF-κB pathway (Schwamborn et al. 2000; Zhu et al.
2007; Sudhakar et al. 2009; Nagabhushana et al. 2011;
Akizuki et al. 2013) and a player in mitotic progression
(Kachaner et al. 2012a, b). It has also emerged as an au-
tophagy receptor (Wild et al. 2011; Tumbarello et al.s examined in the current study. A. The full length of wild type
in, LC3 interacting (LIR, green) motif, coiled-coil (CC, blue) domains, an
tif. Optineurin mutations are indicated. E50K is associated with NTG.
e not been linked to any diseases so far. B. Deletion fragments of
sociated exon 5 deletion mutation and Q398X mutant result in truncation
and are therefore categorized as deletion fragments.
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tivation of TANK binding kinase 1 and interferon regula-
tory factor 3 in immune cells (Sakaguchi et al. 2011;
Munitic et al. 2013) and is noted in addition to be a player
in antiviral immune response (Mankouri et al. 2010). This
protein is moreover demonstrated to interact and/or form
complex with proteins including Rab8, huntingtin (Htt),
myosin VI, and transferrin receptor (TfR). The binding
sites with Rab8, Htt, and myosin VI reside respectively,
between 141–209, 411–461, and 412–520 amino acid resi-
dues of optineurin. All these interacting partners are
known to have a role in membrane trafficking pathways
(Hattula and Peranen 2000; Sahlender et al. 2005; Au et al.
2007; del Toro et al. 2009) and such interactions may be
the basis why optineurin is involved in regulation of
protein trafficking (Hattula and Peranen 2000; Sahlender
et al. 2005; del Toro et al. 2009; Nagabhushana et al. 2010;
Park et al. 2010).
In patients with NTG, mutations including Glu50Lys
(E50K) and 691_692ins AG (2 bp-AG insertion) have
been identified (Rezaie et al. 2002). E50K is a missense
mutation and 2 bp-AG insertion is a nonsense mutation
that leads to truncation of optineurin protein by 76%
(Rezaie et al. 2002). Three mutations in the gene encod-
ing optineurin in Japanese familiar or sporadic ALS pa-
tients have also been reported (Maruyama et al. 2010)
which include a homozygous deletion of exon 5, a homo-
zygous nonsense Gln398 stop (Q398X) and a heterozygous
missense Glu478Gly (E478G). Additional mutations asso-
ciated with ALS have been identified, such as Arg96Leu
(R96L) mutation in French families of ALS patients
(Millecamps et al. 2011).
It has been previously reported that overexpression of
wild type optineurin resulted in formation of bright
granular or punctate structures, termed foci, and fragmen-
tation of the Golgi (Park et al. 2006; Ying et al. 2010). In
addition, impairment of transferrin uptake (Park et al.
2010) and apoptosis (Koga et al. 2010) were observed. In
cells expressing E50K, all these phenotypes were mani-
fested to a greater degree than in the wild type (Park et al.
2006, 2010; Nagabhushana et al. 2010; Ying et al. 2010).
By contrast, cells expressing Leu157Ala (L157A) and
Asp474Asn (D474N) optineurin mutations, evaluated by
Park et al. (2010) and Nagabhushana et al. (2010) respect-
ively, showed minimal foci formation and unaltered trans-
ferrin uptake. Neither mutation, to date, has been linked
to any diseases.
The present study was undertaken to determine whether
the expression of a number of optineurin mutations and
deletion fragments in cell lines RGC5 and/or Neuro2A
would result in the above-mentioned optineurin pheno-
types that include foci formation, Golgi fragmentation,
compromised transferrin uptake and increased apoptotic
activity. A total of 15 green fluorescence protein (GFP)tagged constructs that included wild type optineurin, and
NTG (E50K and 2 bp-AG insertion), ALS (exon 5 dele-
tion, R96L, Q398X, and E478G) and non-disease (L157A
and D474N) associated mutants as well as various deletion
fragments were prepared. These constructs were trans-
fected into cells and the ensuing biological consequences
were evaluated.
Missense mutations E50K and R96L are located in the
N-terminal coiled-coil domain of optineurin while
D474N and E478G are in the C-terminal UBD domain.
By computer analysis (http://2zip.molgen.mpg.de/), the
change of Leu157 to Ala in the optineurin sequence may
lead to obliteration of the leucine zipper. The nonsense
2 bp-AG insertion presumably induces a premature stop
codon that leads to truncations of the optineurin protein
by 76%, yielding a 1-148 fragment. With exon 5 deletion,
the resulting transcript would also be expected to trans-
late into a truncated protein (1–55) with only 55 amino
acids in length (Ying and Yue 2012). Q398stop (Q398X)
mutation in addition would cause truncation, yielding a
fragment with 398 amino acid residues (1–398). These 3
mutations or deletion fragments with truncated C-terminal
UBD domains along with fragments 1–209, 1–424, 210–
424, 217–398, 217–577, and 425–577 lack either the N-
terminal coiled-coil, the leucine zipper, the C-terminal
coiled-coil, and/or the UBD sequences. A schematic repre-




RGC5 cells were obtained from the departmental core
facility at the University of Illinois at Chicago, deposited
by Dr. Paul Knepper (Choi et al. 2005) and generously
provided originally by Dr. Neeraj Agarwal (Aoun et al.
2003; Agarwal 2013). RGC5 cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10%
fetal bovine serum (FBS) and antibiotics (Park et al. 2007;
Koga et al. 2010; Ying et al. 2010; Shen et al. 2011). Mouse
neuronal Neuro2A cells were obtained from Dr. Chunjiang
Yu at the University of Illinois at Chicago (Chakrabarti
et al. 2013). Neuro2A cells were cultured under conditions
similar to RGC5 cells in DMEM supplemented with 10%
FBS.
Plasmid constructs
Expression vectors with enhanced GFP (EGFP) tagged at
the C-terminus of wild type, E50K, and L157A optineurin,
pOPTNWT-EGFP, pOPTNE50K-EGFP and pOPTNL157A-
EGFP, respectively, were constructed as previously described
(Park et al. 2006; Ying et al. 2010; Ying and Yue 2012). Mu-
tant constructs pOPTNR96L-EGFP, pOPTND474N-EGFP, and
pOPTNE478G-EGFP were additionally made based on
pOPTNWT-EGFP by site-directed mutagenesis employing
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from Stratagene (La Jolla, CA) or the GeneTailor™
Site-Directed Mutagenesis System from Invitrogen
(Grand Island, NY). Primers used were listed in
Table 1 with point mutations in boldface. Expression
vectors of fragments of optineurin including pEGFP-
OPTNWT, pEGFP-OPTNexon 5 del, -OPTN1-209, -OPTN1-424,
-OPTN210-424, and -OPTN425-577 were made by polymerase
chain reaction (PCR) amplification using primers
listed in Table 1 and subsequent subcloning into
pEGFP-C1 vector (Clontech, Mountain View, CA).
They were tagged with EGFP at the amino (N)-
terminus. pEGFP-OPTN2 bp-AG insertion and pEGFP-
OPTNQ398X were made by site-directed mutagenesis
based on pEGFP-OPTNWT. Constructs pEGFP-OPTN217-398
and pEGFP-OPTN217-577 were made by digestion of
plasmids pEGFP-OPTNQ398X and pEGFP-OPTNWT with
BglII, gel purification and self-ligation. All the constructs
were verified by sequence analyses.
Immunofluorscence staining
RGC5 or Neuro2A cells plated (7000 cells/well) on
Lab-Tek 8-well CC2 glass chamber slides (NalgeNunc,
Rochester, NY) were transfected with Lipofectamine
LTX transfection reagent (Invitrogen) for 18 hours
and fixed with 4% paraformaldehyde for 15 min. After
permeabilization in 0.2% Triton X-100 for 4 min, the
cells were blocked for 1 hour with 3% bovine serum
albumin (BSA) and incubated at room temperature
for 1 hour with mouse monoclonal anti-GM130 pri-
mary antibody (1:200, BD Biosciences, San Jose, CA).
After a further 1 hour incubation with Cy3-goat anti-
mouse IgG (1:200; Jackson ImmunoResearch Laboratories,
West Grove, PA), the slides were mounted in Vectashield
mounting solution (Vector Laboratories, Burlingame, CA)Table 1 Primer sequences






pEGFP-OPTNwt AAA GAA TTC AAT GTC CCA TCA ACC TCT CAG
pEGFP-OPTN1-55 AAA GAA TTC AAT GTC CCA TCA ACC TCT CAG
pEGFP-OPTN1-209 AAA GAA TTC AAT GTC CCA TCA ACC TCT CAG
pEGFP-OPTN1-424 AAA GAA TTC AAT GTC CCA TCA ACC TCT CAG
pEGFP-OPTN210-424 AAA GAA TTC AAT GGC ATT GTC TAA ATA TAG GAG
pEGFP-OPTN210-577 AAA GAA TTC AAT GGC ATT GTC TAA ATA TAG GAG
pEGFP-OPTN425-577 AAA GAA TTC AAT GGA ACT GAG TGA AAA ACT GGA
Primer sequences used for constructing GFP-tagged optineurin mutant and deletio
in boldface. The restriction enzyme sites that were used in the cloning are in italicscontaining 4′,6-diamidino-2-phenylindole (DAPI). The
fluorescence was visualized on an Axioscope (Carl
Zeiss MicroImaging, Thornwood, NY) with a 63× oil
objective. Approximately 20 images were acquired for
each specimen.
The images were evaluated for formation of foci which
are bright, granular or punctate structures located in the
perinuclear region of the cell (Park et al. 2006; Ying
et al. 2010). Additionally, the percentage of cells with
fragmented Golgi was determined. Golgi fragmentation
was defined as the appearance of disconnected, small
and round Golgi fragments dispersed in the cells (Park
et al. 2006). Cells with compromised Golgi were counted
and the percentage of cells containing fragmented Golgi
relative to the total number of transfected cells was cal-
culated. A minimum of 40 cells were evaluated for each
expression vector per experiment with the exception of
D474N and 2 bp-AG insertion constructs with which
only approximately 20 cells were examined (due to the
low number of transfected cells). Four independent ex-
periments were performed. Results were presented as
the average of the 4 experiments (mean ± SEM).
Transferrin uptake
RGC5 cells plated on Lab-Tek 8-well CC2 glass chamber
slides were transfected for 18 hours. Thereafter, the cells
were washed with phosphate buffered saline (PBS) and
incubated for 1 hour in serum-free DMEM with 0.2%
BSA (DMEM-BSA) to deplete serum. The cells were
then incubated with DMEM-BSA containing 25 μg/ml
of Texas red-transferrin (TR-Tf) (Invitrogen) at 37°C for
0 or 15 min, placed on ice, and washed 3 times with cold
PBS containing 0.2% BSA, 1 mM CaCl2 and 1 mM MgCl2.
Following a wash in cold acid buffer containing 0.2 M






TTT TCT AGA TTA AAT GAT GCA ATC CAT CAC
TTT TCT AGA TCA GTG GGG TCC TTT CAG CTG GTG GTT CTC
TTT TCT AGA TTA CGT GCC AGT GGA GAC TGT TC
TTT TCT AGA TTA CTT CAG CAC TGC CCT GTC CA
TTT TCT AGA TTA CTT CAG CAC TGC CCT GTC CA
TTT TCT AGA TTA AAT GAT GCA ATC CAT CAC
TTT TCT AGA TTA AAT GAT GCA ATC CAT CAC
n fragment expression plasmids are listed. The mutated nucleotides are labeled
.
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Images were acquired with Leica SP2 confocal system
(Leica Microsystems, Bannockburn, IL) with a 40× dry ob-
jective using sequential scanning to minimize the bleed
through.
The uptake of TR-Tf was quantified as described by
Park et al. (2010). In brief, the outline of single cell was
drawn and using Leica confocal software, the average
fluorescence intensity of TR-Tf inside the cell was mea-
sured. A region without any fluorescence, which served as
the background, was subtracted from the red fluorescence
intensity in the cell. The resulting intensity was multiplied
by the area of the cell for the total intensity. The values
for at least 40 transfected and 40 non-transfected cells in
approximately 10 different visual fields were averaged. Five
sets of independent experiments were performed. The in-
tensity of TR-Tf for each construct was presented as the
average (mean ± SEM) of 5 experiments.
Apoptosis
Apoptosis was evaluated using the Biomol CV-caspase 3
and 7 detection kit (Enzo Life Sciences, Inc, Farmingdale,
NY). The kit utilizes a fluorophore, cresyl violet, coupled
to the C-terminus of the optimal tetrapeptide recognition
sequences for caspase 3 and 7, DEVD (CR(DEVD)2) (Koga
et al. 2010). Once target sequences are cleaved by the
activated enzymes, red fluorescence throughout the
cell is visualized, indicative of apoptotic activity. Briefly,
cells on chamber slides transiently transfected for 48 hours
were incubated with [CR(DEVD)2] in DMEM for 60 min.
Following incubation with Hoechst stain for 5 min, the
cells were fixed in 4% paraformaldehyde. The slides were
mounted and imaged immediately with fluorescence
microscopy using a 40× oil objective. Images from 20
randomly selected areas were acquired.
Approximately 60 cells for each construct per experi-
ment were evaluated for apoptotic activity. The number
of transfected cells with positive caspase 3/7 activity (red
and green fluorescence) and total number of transfected
cells (only green) were counted. The percentage of apop-
totic cells was calculated from these numbers. Five inde-
pendent experiments were performed. Data from 2
complete experiments were averaged.
Immunoprecipitation and Western blotting
To examine the binding of optineurin and mutants with
endogenous Rab8 and TfR, RGC5 cells were transfected
with pOPTNWT-EGFP, pOPTNE50K-EGFP, pOPTNR96L–
EGFP, pOPTNE478G–EGFP, pEGFP-OPTNQ398X, pEGFP-
OPTN2 bp-AG insertion, and pEGFP-N1 (control) for 24
hours. Immunoprecipitation was performed using μMACS
GFP Isolation Kit (MiltenyiBiotec, Auburn, CA) and
MultiMACS™ M96/M96 thermo Separators (MiltenyiBiotec)
following manufacturer’s protocol. In brief, cells werelysed in lysis buffer (50 mM Tris–HCl, 150 mMNaCl, 1%
Triton X-100, pH 8.0) supplemented with a protease in-
hibitor mixture (Sigma). Clear cell lysate was incubated
with 50 μl of anti-GFP microbeads to magnetically label
the GFP-tagged protein for 30 min on ice. The μ column
was installed on MultiMACS™ M96/M96 thermo Separa-
tors and magnetic field was applied. The μ column was
equilibrated with equilibration buffer and then the lysate-
microbeads mixture was loaded. After washing with 4 ×
200 μl of lysis buffer and 1 × 100 μl of low salt wash buffer
(20 mM Tris–HCl, pH 7.5), 20 μl of pre-heated 95°C hot
elution buffer (1× SDS loading buffer) was applied to the
column and incubated at room temperature for 5 min. Fi-
nally 80 μl of pre-heated 95°C elution buffer was applied
to the column and elutes were collected. The elutes were
subjected to SDS-PAGE under reducing conditions. The
proteins were transferred to nitrocellulose membrane, and
the level of co-precipitated endogenous TfR and Rab8
were assessed by mouse anti-Rab8 (BD Biosciences) and
anti-TfR (Zymed Laboratories, San Francisco, CA) mono-
clonal antibodies. The pulled down optineurin-GFP fusion
protein or GFP control was evaluated by rabbit anti-GFP
polyclonal antibody (Santa Cruz Biotechnology, Santa
Cruz, CA). The blot was further incubated for 1 hour with
horseradish peroxidase-conjugated secondary antibody
(1:10,000; Jackson ImmunoResearch Laboratories, West
Grove, PA). Immunoreactive protein bands were detected
by chemiluminescence using SuperSignal substrate (Pierce).
Densitometry was performed. The band intensity of the
co-precipitated Rab8 or TfR was normalized to that of
optineurin-GFP (indicated as a ratio).
Total cell lysates from RGC5 cells transfected with
pEGFP-N1, pOPTNWT-EGFP or pOPTNE50K-EGFP were
also immunoprecipitated with rabbit anti-optineurin
(C-Term) polyclonal antibody (Cayman Chemical, Ann
Arbor, MI). Lysate of non-transfected RGC5 cells was
immunoprecipitated with rabbit normal IgG as a negative
control. The pulled down protein was immunoblotted
with anti-TfR, anti-Rab8, or anti-optineurin. The band in-
tensities of Rab8 and TfR were normalized to those of the
endogenous optineurin or optineurin-GFP. The mem-
branes were additionally stripped and re-probed with anti
β-catenin (Santa Cruz Biotechnology) to verify the specifi-
city of immunoblotting.
Statistical analysis
One-way ANOVA was performed as a statistical meas-
ure for significance of the data. Statistical significance
was noted if P < 0.05.
Results
Foci formation
In RGC5 cells transfected to express wild type and E50K
optineurin-GFP, bright granular structures (foci) in perinuclear
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strated (Park et al. 2006; Ying et al. 2010). R96L, located
in the domain close to E50K, resulted in similarly promin-
ent foci formation. Foci by contrast were not observed
with mutations in the UBD domain, D474N and E478G.
Foci were also not discerned with exon 5 deletion (1–55)
and Q398X (1–398) mutations and deletion fragments
1–209, 1–424, 210–424 and 217–398 in which either
the UBD or the N-terminal leucine zipper sequences
were lacking or truncated (Figure 2). In cells express-
ing L157A, and fragments 217–577 and 425–577, foci
were occasionally noted but the foci were atypical in
that they were small in size, low in number, and were
more spread out, not concentrated in the perinuclearFigure 2 Foci formation in RGC5 cells. Cells transfected with pEGFP-N1
deletion fragment constructs were observed by fluorescence microscopy 2
in perinuclear regions were prominently observed in cells expressing optin
D474N, E478G and deletion fragments 1–55, 1–148, 1–209, 1–398, and 1–4
and 425–577 (not shown), foci were typically not detected. Foci were note
not concentrated in the perinuclear area. Note nuclear location of deletionarea. The 2 bp-AG insertion mutant (1–148 fragment)
was expressed and localized in the nucleus (Figure 2).
These findings were similarly demonstrated in Neuro2A
cells (Figure 3).
Golgi fragmentation
To examine the integrity of the Golgi apparatus, RGC5
and Neuro2A cells were immunostained with anti-GM130,
a Golgi marker. Non-transfected and GFP-expressing
control cells showed robust GM130 staining and Golgi
apparatus. In RGC5 cells expressing wild type, E50K,
R96L, and Q398X optineurin however, the Golgi complex
was disconnected, smaller, and appeared to be frag-
mented (Figure 4A). The percentage of cells displaying(mock control), GFP-tagged optineurin wild type, mutants as well as
4 hours post transfection. Bright granular structures (foci, arrowheads)
eurin wild type, E50K, and R96L, but not at all in those expressing
24. In cells expressing mutant L157A and deletion fragments 217–577
d occasionally, but they were small in size, low in number, and were
fragment 1–148. Scale bar, 20 μm.
Figure 3 Foci formation in Neuro2A cells. Cells transfected with pEGFP-N1 (mock control), GFP-tagged optineurin wild type, mutants as well as
deletion fragment constructs were observed by fluorescence microscopy 24 hours post transfection. Bright granular structures (foci, arrowheads)
in perinuclear regions were prominently observed in cells expressing optineurin wild type, E50K, and R96L, but not in the cells transfected with
other mutant or deletion constructs. Note that fragment 1–148 was expressed in the nucleus. Scale bar, 20 μm.
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23.5 ± 5.5%. and 25.8 ± 6.1%, respectively for wild type,
E50K, R96L, and Q398X optineurin) was significantly
(P < 0.033) higher than that in GFP (9.8 ± 3.7%) and
non-transfected (8.4 ± 3.3%) normal controls. The per-
centage of Golgi-fragmented cells was moderately in-
creased in RGC5 cells overexpressing E478G (17.5 ±
6.3%), fragment 1–424 (17.4 ± 4.7%) and fragment 217–
577 (18.5 ± 4.9%), although their values did not reach
statistical significance. The percentages of RGC5 cells
with Golgi fragmentation in L157A, D474N, exon 5
deletion (1–55), and 2 bp-AG insertion (1–148) mu-
tants as well as 1–209, 210–424, 217–398, and 425–577
fragments were similar to controls (Figure 4B). Golgi
staining of Neuro2A cells yielded comparable results (data
not shown).Transferrin uptake
To assess the effect of forced expression of optineurin
mutations and deletion fragments on transferrin uptake,
RGC5 cells after transfection were incubated with TR-Tf
for 15 min. The accumulation of TR-Tf in cells express-
ing the various constructs was shown in Figure 5A. Cells
transfected with GFP had a similar level of TR-Tf red
fluorescence as non-transfected cells. By comparison,
cells transfected with wild type, E50K, R96L, 2 bp-AG
insertion (1–148) and Q398X (1–398) optineurin had a
lower TR-Tf intensity. Cells transfected with the remaining
mutants and fragments, in contrast, all exhibited a similar
level of fluorescence as mock control and non-transfected
cells (Figure 5A).
The level of the accumulated TR-Tf in transfected cells
was quantified. As shown in Figure 5B, the transferrin
Figure 4 (See legend on next page.)
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Figure 4 Golgi fragmentation. A. RGC5 cells transfected with pEGFP-N1 (mock control), GFP-tagged optineurin wild type, mutants or deletion
fragment constructs were immunostained with anti-GM130 (Golgi marker, in red). Representative images of wild type, E50K, R96L, L157A, D474N,
E478G, as well as deletion fragments 1–55, 1–148, 1–209, 1–398, 1–424, and 217–577 are shown. The nuclei were stained with DAPI in blue and
transfected cells are in green. Severe Golgi fragmentation was observed in cells with prominent perinuclear foci formation such as wild type,
E50K and R96L. The Golgi fragmentation however could still occur even without robust foci formation such as in Q398X (1–398). The percent of
cells with fragmented Golgi was also increased with E478G, 1–424, and 217–577, but the values did not reach statistical significance. Higher
magnification image of a transfected green cell indicated with a white star is shown in the inset. Scale bar, 10 μm. B. The percentage of cells with
Golgi fragmentation was quantified. Compared to non-transfected normal or GFP mock controls, significantly more cells showed Golgi fragmentation
in wild type, E50K, R96L and 1–398 transfected cells. **P < 0.033 compared to normal non-transfected or GFP controls. There was a moderate increase
of cells with Golgi fragmentation in E478G, 1–424, and 217–577 transfected cells. All remaining mutations and deletion fragments showed no
difference from controls.
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neurin was significantly decreased (P < 0.0022) compared
with GFP control, corroborating previous results (Park
et al. 2010; Ying et al. 2010). The impairment of trans-
ferrin uptake in cells expressing E50K (37%, average per-
cent difference in comparison to GFP cells) was more
pronounced than those expressing wild type optineurin
(30%). Cells expressing R96L, 2 bp-AG insertion, and
Q398X optineurin also had a significant decrease in trans-
ferrin uptake (~18–36%, P < 0.031 compared with GFP
control) (Figure 5B). D474N and E478G showed only ap-
proximately 10%, non-significant reduction in transferrin
uptake.
The transferrin uptake in RGC5 cells expressing
L157A optineurin was unaltered (P > 0.05), in agreement
with studies by Park et al. (2010). Cells transfected with
the remaining optineurin fragments that lacked either
the N- or C-terminal sequences or both did not exhibit
any defect in the transferrin uptake (Figure 5B).
Apoptosis
Apoptosis in RGC5 cells transfected with various opti-
neurin mutants and deletion fragments was probed with
an active caspase 3/7 kit. Figure 6A shows representative
images for each of the optineurin mutants and deletion
fragments. Apoptotic cells were seen as active caspase
3/7-containing red fluorescent cells.
The percentage of apoptotic cells in each specimen
was quantified (Figure 6B). The value was low in non-
transfected and GFP mock controls (2.9% ± 1.3). Cells
expressing wild type, E50K, R96L, Q398X (1–398) and
2 bp-AG insertion (1–148) optineurin all displayed sig-
nificantly (P < 0.0031) increased levels of apoptotic activ-
ity (8.8 ± 2.1%, 10.8 ± 4.1%, 8.3 ± 3.1%, 8.2 ± 3.7%, 28.6 ±
11.9%, respectively) compared to GFP controls. Among
them, the 2 bp-AG insertion mutant induced the highest
level of apoptosis. L157A optineurin expression in cells
did not show evidence of enhanced apoptosis (2.8% ± 0.6
compared with GFP control). The level of apoptosis in
cells transfected with D474N and E478G mutants and
the optineurin fragments remained in the normal range,
similar to that of mock controls (Figure 6B).Levels of co-precipitated endogenous Rab8 and TfR
Rab8 and TfR have been shown to interact with opti-
neurin (Ying et al. 2010). The level of these molecules
co-immunoprecipitated with GFP in RGC5 cell lysates
was examined by Western blotting. E50K-, R96L-, Q398X-
and E478G-GFP fusion proteins showed more Rab8
co-pulled down than the wild type optineurin-GFP
(Figure 7A). The ratio after normalization with the total
amount of optineurin-GFP pulled down was: wild type
(1.0), E50K (2.3), R96L (1.3), Q398X (0.9) and E478G
(1.4), respectively. The mutants likewise pulled down
more endogenous TfR (Figure 7B). The normalized ratio
to wild type (1.0) was: E50K (2.6), R96L (2.1), Q398X
(1.3), and E478G (1.2), respectively. The pull down experi-
ment with 2 bp-AG insertion-GFP failed, likely due to
the fact that this fragment was very toxic, causing se-
vere cell death (data not shown). Negative mock con-
trol EGFP-N1, as expected, did not pull down Rab8
and TfR (Figure 7A, B).
Cell lysates of RGC5 cells transfected with pEGFP-N1,
and wild type or E50K optineurin-EGFP expression vec-
tors were also immunoprecipitated with anti-optineurin
polyclonal antibody and immunoblotted with anti-Rab8,
anti-TfR or anti-optineurin. The Rab8/endogenous opti-
neurin values from wild type and E50K optineurin-GFP-
expressing cells were 2.7 and 3.6 fold higher, respectively,
than that of the GFP control (Figure 7C, top panel). The
TfR/endogenous optineurin values were likewise higher
(1.6 and 2.5 fold, respectively) in pOPTNWT- and pOPT-
NE50K-EGFP-transfected cells (Figure 7C, middle panel).
These results indicated that relative to EGFP-N1 control
or the normal situation, the Rab8 or TfR binding was
increased by 2–3 fold upon overexpression of wild
type and E50K optineurin-GFP. Since the Rab8 and
TfR optineurin-GFP-co-precipitated levels were similar
to, or greater than, those of the wild type (Figure 7A, B),
mutants such as R96L and Q398X were also deduced to
confer an enhanced binding capacity for these proteins.
Total cell lysate of non-transfected RGC5 cells, when
immunoprecipitated with rabbit normal IgG showed no
reactivity with either Rab8, TfR or optineurin antibody
(negative control). The membranes were further stripped
Figure 5 Transferrin uptake. RGC5 cells transfected with pEGFP-N1 (mock control) or one of the optineurin expression vectors were incubated
with Texas red-transferrin (TR-Tf). Representative micrographs for GFP, and optineurin wild type (OPTNWT)-, OPTNE50K-, OPTNR96L-, OPTND474N-,
OPTN1-148-, OPTN1-398-, OPTN210-424-, and OPTN217-577-GFP expressing cells are shown (A). The internalized TR-Tf is in red and the transfected cells
are indicated as white stars (green channel is shown in the inset). Scale bar, 20 μm. The internalization of TR-Tf in transfected cells and non-transfected
cells was quantified (B). Compared to GFP mock control and non-transfected normal control, cells expressing wild type, E50K, R96L, 2 bp-AG insertion
(1–148), and Q398X (1–398) optineurin had a reduced TR-Tf uptake (*, P < 0.031). The uptake impairment phenotype was not observed with E478G
mutation or any other deletion fragments. Scale bar, 20 μm.
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Figure 6 Apoptosis. RGC5 cells transfected with pEGFP-N1 (mock control) or one of optineurin expression vectors were incubated with caspase
3/7 substrate and Hoechst. A. Representative micrographs for GFP, and GFP-tagged optineurin wild type, E50K, R96L, L157A, E478G, 1–55, 1–148,
1–209, 1–398, 1–424, and 217–577 expressing cells are shown. The nuclei are stained in blue, the caspase3/7 positive cells (indicated by arrow-
heads) are in red and the transfected cells are in green (inset). Apoptosis was observed in cells expressing wild type, E50K, R96L, 2 bp-AG insertion
(1–148) and Q398X (1–398) optineurin but not in those expressing L157A or remaining mutants and deletion fragments. Scale bar, 20 μm.
B. Quantification of percentage of cells with apoptosis also showed similar trend as in A. *P < 0.0031.
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Figure 7 (See legend on next page.)
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Figure 7 The level of Rab8 (A) and TfR (B) co-precipitated with optineurin-GFP (OPTN-GFP). RGC5 cells were transfected with pEGFP-N1,
and GFP-tagged wild type, E50K, R96L, Q398X, and E478G optineurin constructs. OPTN-GFP was immunoprecipitated with anti-GFP microbeads.
Pulled down protein was immunoblotted with anti-GFP to verify the immunoprecipitation (IP) procedure. Co-precipitated proteins were immunoblotted
(IB) with anti-Rab8 (A), anti-TfR (B), or anti-GFP antibody. Densitometry was performed to quantify the intensity of Rab8, TfR and OPTN-GFP bands.
The values were normalized against OPTN-GFP and the ratios between the mutants and wild type optineurin are presented. Note that
the levels of Rab8 and TfR co-precipitated with OPTN-GFP in the mutants were similar to, or higher than, those in the wild type. As was
expected, no Rab8 or TfR protein co-precipitation with GFP (25 kDa, asterisks) was detected in lysates collected from cells transfected with
EGFP-N1 empty vector (C). The levels of Rab8 and TfR co-precipitated with optineurin. RGC5 cells were non-transfected, or transfected
with pEGFP-N1, or GFP-tagged wild type or E50K optineurin construct. Optineurin-GFP (OPTN-GFP) and endogenous optineurin (OPTN)
were immunoprecipitated with anti-optineurin polyclonal antibody. Non-transfected RGC5 cell lysate was immunoprecipitated with normal
IgG as negative control. The pulled down protein was immunoblotted with anti-Rab8 (top panel), anti-TfR antibody (middle panel) or anti-optineurin
antibody (bottom panel, for verification of the IP procedure). Normal IgG did not yield any band for TfR or Rab8 as was expected. The ratios of
Rab8/endogenous OPTN (top panel) and TfR/endogenous OPTN (middle panel) from wild type and E50K optineurin-GFP-expressing cells were higher
than those of GFP control.
Turturro et al. SpringerPlus 2014, 3:99 Page 13 of 16
http://www.springerplus.com/content/3/1/99and re-blotted with an irrelevant antibody, anti-β-catenin,
as an additional control. Signal was not detected on any of
the blots (data not shown).
Discussion
The current study examined the biological consequences
of a series of mutations and sequence deletions in the
optineurin gene to determine correlations between bio-
molecular functions and specific structural elements.
The results presented in Figures 2, 4, 5, and 6 are sum-
marized in Table 2.Table 2 Summary of optineurin phenotypes resulting
from forced expression of optineurin mutants and










Y Y Y Y
E5OK Y Y Y Y
R96L Y Y Y Y
L157A N* N N N
D474N N N N N
E478G N Y/N Y/N N
1–55 N N N N
1–148 N** N Y Y
1–209 N N N N
1–398 N* Y Y Y
1–424 N Y/N N N
210–424 N N N N
217–398 N N N N
217–577 N* Y/N N N
425–577 N* N N N
Results from Figures 2, 4, 5, and 6 are summarized. Y: positive phenotype;
Y/N: mild to no phenotype; N: no phenotype.
*Foci, even when formed were small in size, low in number and not in
perinuclear regions.
**Nuclear localization was observed.E50K, a mutation located in the N-terminal coiled-coil
domain of optineurin, demonstrates prominent pheno-
types that include foci formation, Golgi fragmentation,
impairment in transferrin uptake and apoptosis. R96L,
another mutation located nearby, also yielded all, albeit
less pronounced phenotypes. E50K is a mutation preva-
lent in patients with NTG (Rezaie et al. 2002) who often
suffer glaucomatous defects more severe than those
without E50K mutation (Aung et al. 2005). The current
data, in agreement with those published previously by
our laboratory and by others (Park et al. 2006, 2010;
Nagabhushana et al. 2010; Kryndushkin et al. 2012),
indicate that E50K is a gain-of-function mutation. A
stronger-than-the-wild type interaction of the E50K mu-
tant with Rab8 and TfR was observed (Figure 7A, B, C)
(Nagabhushana et al. 2010; Park et al. 2010). We speculate
that this mutation may generate a conformational change
to promote protein interactions. The PROSITE analysis
(Bairoch et al. 1997) however suggests that introduction
of E50K mutation results in no particular change either in
the structure or the conformation of optineurin (data not
shown). A more definitive conclusion has to await high-
resolution structural determination by X-ray crystallog-
raphy. R96L, a missense mutation found in patients with
ALS also appears to be a gain-of-function mutation with
an enhanced binding with Rab8 and TfR (Figure 7A, B).
The binding was nevertheless somewhat weaker than
that seen with E50K. The weaker binding may be the
basis why the R96L phenotypes were milder than those of
E50K.
L157A mutation has not been identified clinically in
any patients to date and is more than likely not disease
causing or related. As stated above, the mutation may
lead to obliteration of the leucine zipper in the opti-
neurin sequence. L157A mutant has been shown to
interact with Rab8 and TfR in a much reduced capacity
(Park et al. 2010), suggesting that the optineurin associ-
ation with Rab8 and TfR requires, at least in part, an in-
tact leucine zipper motif.
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two mutations in the UBD domain, D474N and E478G.
It seems that the foci formation was abrogated by muta-
tions in either the leucine zipper or the UBD domain.
Foci were also not noted when cells were transfected to
express optineurin mutations/fragments with sequence
deletion(s) in either or both of the domains such as
1–209, Q398X (1–398), 1–424, and 217–577. The intact
sequences of both leucine zipper and UBD domains are
thus concluded to be required for the perinuclear foci
formation phenotype. This notion is somewhat differ-
ent from that described in a recent report in which
aggregates (foci) were seen in yeast with fragments
1–251, 1–398, 182–577, and 98–398 (Kryndushkin
et al. 2012), as long as one of the coiled-coil domains
was present. The disparity in results could be related
to difference in the systems used (in vitro mouse cell
culture versus in vivo yeast model), and also the definition
or pattern of foci or aggregates formed.
While all optineurin phenotypes are observed when
foci are formed with mutants (such as E50K and R96L),
the formation does not necessarily predict the other phe-
notypes. One example is the fragment Q398X (1–398),
which, with no foci manifestation, resulted in Golgi frag-
mentation, defective transferrin uptake and apoptosis. The
foci are likely formed by self binding of optineurin mole-
cules as well as their interactions with proteins including
Rab8, myosin VI and TfR, requiring at least in part, intact
leucine zipper and UBD motifs. Overabundance or accu-
mulation of the protein/fragment and perturbation of the
protein interactions conceivably would drive foci forma-
tion. The role or significance of the foci observed is at
present uncertain. Optineurin foci are reminiscent of the
inclusion bodies, Lewy bodies or aggresomes detected in
neurodegenerative diseases (Grune et al. 2004). The inclu-
sion bodies and aggresomes once were considered to be
the culprit for neurodegenerative diseases. More recent
evidence however suggests that they may play protective
role by sequestering toxic, misfolded protein species and
providing the cells with an opportunity of delayed protein
degradation (Garcia-Arencibia et al. 2010; Zerovnik 2010).
They may also inactivate the proteasome and mediate
cytotoxicity (Glick et al. 2010). The optineurin foci may
likewise have a protective role. The foci may nevertheless
also signify that the cells are burdened to the extent of be-
yond protection. Our laboratory has shown that the prote-
asome activity is compromised and autophagy is induced
when cells overexpress wild type and E50K optineurin
(Shen et al. 2011). A very recent study on another opti-
neurin variant, M98K, has further linked the autophagic
process to apoptosis in RGC5 cells (Sirohi et al. 2013).
It was speculated (Ying and Yue 2012) that alterations
in the interaction between optineurin and its binding
partners (such as Rab8, myosin VI, and Htt) may disturbthe balance between actin- and microtubule-based motor
systems and contribute to fragmentation of the Golgi
complex. Consistent with this hypothesis, Golgi fragmen-
tation was noted with wild type optineurin and mutants
E50K, R96L and Q398X (or fragment 1–398), all of
which demonstrated an enhanced Rab8 binding cap-
acity (Figure 7A, C). E478G mutant that resulted in Golgi
fragmentation at a mild level (Figure 4) also showed stron-
ger binding with Rab8 (Figure 7A). With deletion in the
N-terminal sequences (fragment 217–577) and deletions
of the C-terminal Htt or myosin VI-binding sequences
(fragment 1–424), mild Golgi fragmentation was likewise
observed (Figure 4). However, when both the N-terminal
Rab8-binding and the C-terminal protein binding domains
were missing (fragments 1–55, 210–424, and 217–398),
no Golgi fragmentation resulted. Exceptions however were
seen that include D474N mutant and fragments 1–209
and 425–577. It is possible that in those situations, the
binding disturbance was not sufficient to induce any Golgi
defect.
A heightened optineurin binding with TfR has been
implicated as a factor leading to impairment of the
transferrin uptake (Park et al. 2010). Apoptosis may en-
sue either from the trafficking impairment and/or the
Golgi fragmentation. In accordance with these hypoth-
eses, wild type optineurin and E50K, R96L, and Q398X
(1–398) mutants that confer the transferrin uptake
phenotype all exhibit a strong binding capacity with TfR
(Figure 7B, C). This same set of optineurins also induced
apoptosis in cells, suggesting that the protein trafficking
phenotype may be correlated with apoptosis, more so
than the Golgi fragmentation. Of note is that fragment
1–424, contrasting Q398X, did not impact transferrin up-
take or apoptosis level. This fragment is only 26 amino
acid residues longer than Q398X. Perhaps addition of se-
quences between residues 399 and 424 enables the protein
to adopt into a different, non-consequential conformation.
E478G had an elevated ratio of TfR co-precipitated with
optineurin-GFP (with a ratio of 1.2 relative to the wild
type, Figure 7B) but provoked only about 10%, non-
significant reduction in the transferrin uptake (Figure 5B).
The nonsense 691_692insAG or the optineurin frag-
ment 1–148 (also called c.382_383insAG or 2 bp-AG in-
sertion) mutation that presumably induces a premature
stop codon in exon 6, stands out from others as it has a
nuclear localization. Clinically, it was identified both in
patients with glaucoma (Rezaie et al. 2002) and a patient
with young ALS onset (46 years) and rapid disease pro-
gression (21 months) (Millecamps et al. 2011). Opti-
neurin does not contain nuclear localization sequences.
It has however been reported that optineurin is translo-
cated to the nucleus in response to oxidative stress (De
Marco et al. 2006). At mitotic entry, Plk1 phosphorylates
optineurin and dissociates it thereby from the Golgi-
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cleus (Kachaner et al. 2012a). While the mechanism is
unclear, the finding that the 2 bp-AG insertion variant
localizes in the nucleus indicates that the localization de-
terminants reside in the first 148 N-terminal sequences.
This mutation is highly toxic, drastically raising the level
of apoptosis in cells (Figure 6). The cause of cell death,
seemingly unrelated to either the Golgi or the transferrin
uptake defect, remains to be determined.
E478G, a missense mutation in the UBD region, is as-
sociated with ALS. Patients with heterozygous E478G
mutation had later onset with slower progression (Ito
et al. 2011). It was suggested that the E478G mutant
might have a dominant-negative effect. Consistent with
our data, optineurin inclusion bodies were not promin-
ent in the patients. A mild case of Golgi fragmentation
was observed (Ito et al. 2011; Figure 4). The E478G mu-
tation in the UBD domain may conceivably interfere
with NF-κB and anti-viral signaling, leading to pathology
under stress conditions such as inflammation and patho-
gen invasion. It is on the other hand, unclear why muta-
tion D474N, also at the UBD domain very close to the
E478G mutation, does not manifest any phenotypes and
is not disease-associated so far. Again, a detailed, high-
resolution 3-dimensional optineurin structure will be re-
quired for a clearer perspective.
RGC5, an immortalized cell line established by trans-
forming postnatal day 1 rat retinal cells with E1A adeno-
virus (Aoun et al. 2003; Agarwal 2013) has been used
widely and extensively as a model of RGC for various in-
vestigations (Harvey and Chintala 2007; Yang et al. 2009).
A re-characterization by Van Bergen et al. (2009) utilizing
both mitochondrial and nuclear DNA analysis however
led to the conclusion that this cell line was of mouse ori-
gin rather than rat. More recently, an investigation by the
original RGC5 cell line creator Krishnamoorthy et al.
(2013) presented evidence indicating that the RGC5 cell
line shared approximately 95% (60/63 of total) of genetic
markers with a mouse derived photoreceptor cell line
(661W). In the present study, in addition to RGC5 cells,
we also evaluated the foci formation and Golgi frag-
mentation phenotypes in a mouse brain neuroblastoma
Neuro2A cell line. Results similar to those from RGC5
cells were observed (Figure 3). Previously, our group has
likewise demonstrated optineurin phenotypes in other
wild type and E50K optineurin-expressing cells including
human retinal pigment epithelial, human trabecular mesh-
work and rat neuronal PC12 cells (Park et al. 2006, 2010;
Koga et al. 2010; Shen et al. 2011). We thus surmise that
the phenotypes may not be cell type dependent, but likely
represent cellular changes induced by optineurin expres-
sion or mutations.
In summary, the current study correlates the biologic
consequences with structural elements in the optineuringene. Lending support to previous investigations, our re-
sults depict that optineurin exerts different functions
and impacts various biologic processes through interac-
tions with other proteins. The study provides clues as to
what regions of the gene may play a critical role in the
development of pathologic consequences. It also under-
scores the need of X-ray crystallography work for the 3-
dimensional structure to analyze conformational changes
in relation to biomolecular functional consequences in-
duced by mutations or truncations.
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